Regen BioPharma, Inc.
RGBP
$0.00
$0.000.00%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | 0.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 0.00% | 0.00% | |||
| SG&A Expenses | -83.62% | -47.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -83.79% | -65.15% | |||
| Operating Income | 115.94% | 72.14% | |||
| Income Before Tax | -164.30% | 202.48% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -164.30% | 202.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -164.30% | 202.48% | |||
| EBIT | 115.94% | 72.14% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -118.52% | 155.67% | |||
| Normalized Basic EPS | -117.65% | 155.74% | |||
| EPS Diluted | -118.52% | 155.67% | |||
| Normalized Diluted EPS | -117.65% | 155.74% | |||
| Average Basic Shares Outstanding | 232.83% | 85.67% | |||
| Average Diluted Shares Outstanding | 232.83% | 85.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||